Literature DB >> 28521493

Clinicopathological significance and impact on outcomes of the gene expression levels of IGF-1, IGF-2 and IGF-1R, IGFBP-3 in patients with colorectal cancer: Overexpression of the IGFBP-3 gene is an effective predictor of outcomes in patients with colorectal cancer.

Naoto Yamamoto1, Takashi Oshima1, Kazue Yoshihara1, Toru Aoyama1, Tsutomu Hayashi1, Takanobu Yamada1, Tsutomu Sato1, Manabu Shiozawa1, Takaki Yoshikawa1, Soichiro Morinaga1, Yasushi Rino1, Chikara Kunisaki2, Katsuaki Tanaka2, Makoto Akaike1, Toshio Imada1, Munetaka Masuda1.   

Abstract

The insulin-like growth factors (IGF) system is involved in tumor proliferation, invasion and metastasis in cancer. The current study investigated the association of IGF-1, IGF-2 and IGF-1 receptor (IGF-1R), IGF binding proteins type 3 (IGFBP-3) mRNA expression levels with clinicopathological characteristics and outcomes of 202 patients with untreated colorectal cancer (CRC). IGF-1, IGF-2, IGF-1R and IGFBP-3 mRNA expression levels were analyzed in surgical specimens of cancer tissues and adjacent normal mucosa cells using reverse transcription-quantitative polymerase chain reaction. The IGF-1R gene expression level was significantly higher in cancer tissue compared with adjacent normal mucosa. By contrast, IGF-1 gene expression levels were reduced in cancer tissue compared with normal mucosa. IGF-2 and IGFBP-3 gene expression levels did not differ significantly between cancer tissue and adjacent normal mucosa. As for the association of gene expression and clinicopathological characteristics, IGFBP-3 gene expression was significantly associated with lymph node metastasis. High IGFBP-3 gene expression was associated with poor 5-year overall survival compared with patients with low IGFBP-3 expression. Furthermore, IGFBP-3 gene expression was identified as an independent prognostic factor using multivariate analysis. Overexpression of the IGFBP-3 gene is considered an effective independent predictor of outcomes in patients with CRC.

Entities:  

Keywords:  biomarker; colorectal cancer; insulin-like growth factor-1; insulin-like growth factor-1 receptor; insulin-like growth factor-2; insulin-like growth factor-binding protein-3; prognostic factor; survival

Year:  2017        PMID: 28521493      PMCID: PMC5431307          DOI: 10.3892/ol.2017.5936

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  39 in total

1.  Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients.

Authors:  K Mita; M Nakahara; T Usui
Journal:  Int J Urol       Date:  2000-09       Impact factor: 3.369

2.  [Relationship between insulin-like growth factor II and prognosis of colorectal cancer].

Authors:  Z Xu; F Liu; X Qi; J Li
Journal:  Zhonghua Wai Ke Za Zhi       Date:  1999-12

3.  The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis.

Authors:  Vassiliki A Papadimitrakopoulou; Erika N Brown; Diane D Liu; Adel K El-Naggar; J Jack Lee; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer Lett       Date:  2005-09-21       Impact factor: 8.679

4.  Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon.

Authors:  S Freier; O Weiss; M Eran; A Flyvbjerg; R Dahan; I Nephesh; T Safra; E Shiloni; I Raz
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

5.  Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.

Authors:  Masayuki Furukawa; Mark Raffeld; Carmen Mateo; Akio Sakamoto; Terry W Moody; Tetsuhide Ito; David J Venzon; Jose Serrano; Robert T Jensen
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

6.  High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.

Authors:  Shinichi Aishima; Yuji Basaki; Yoshinao Oda; Yousuke Kuroda; Yunosuke Nishihara; Kenichi Taguchi; Akinobu Taketomi; Yoshihiko Maehara; Fumihito Hosoi; Yuichiro Maruyama; Abbas Fotovati; Shinji Oie; Mayumi Ono; Takato Ueno; Michio Sata; Hirohisa Yano; Masamichi Kojiro; Michihiko Kuwano; Masazumi Tsuneyoshi
Journal:  Cancer Sci       Date:  2006-09-12       Impact factor: 6.716

7.  Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer.

Authors:  Ichitarou Shiratsuchi; Yoshito Akagi; Akihiko Kawahara; Tetsushi Kinugasa; Kansakar Romeo; Takefumi Yoshida; Yasuhiko Ryu; Yukito Gotanda; Masayoshi Kage; Kazuo Shirouzu
Journal:  Anticancer Res       Date:  2011-07       Impact factor: 2.480

Review 8.  Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.

Authors:  Peter E Clayton; Indraneel Banerjee; Philip G Murray; Andrew G Renehan
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

9.  Insulin-like growth factor binding protein-3 is overexpressed in endothelial cells of mouse breast tumor vessels.

Authors:  Michael C Schmid; Marco Bisoffi; Antoinette Wetterwald; Elsbeth Gautschi; George N Thalmann; Stefania Mitola; Federico Bussolino; Marco G Cecchini
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

10.  Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies.

Authors:  Sabina Rinaldi; Rebecca Cleveland; Teresa Norat; Carine Biessy; Sabine Rohrmann; Jakob Linseisen; Heiner Boeing; Tobias Pischon; Salvatore Panico; Claudia Agnoli; Domenico Palli; Rosario Tumino; Paolo Vineis; Petra H M Peeters; Carla H van Gils; Bas H Bueno-de-Mesquita; Alina Vrieling; Naomi E Allen; Andrew Roddam; Sheila Bingham; Kay-Tee Khaw; Jonas Manjer; Signe Borgquist; Vanessa Dumeaux; Inger Torhild Gram; Eiliv Lund; Antonia Trichopoulou; Georgios Makrygiannis; Vassiliki Benetou; Esther Molina; Ignacio Donate Suárez; Aurelio Barricarte Gurrea; Carlos A Gonzalez; Maria-Jose Tormo; Jone M Altzibar; Anja Olsen; Anne Tjonneland; Henning Grønbaek; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Sophie Morois; Nadia Slimani; Paolo Boffetta; Mazda Jenab; Elio Riboli; Rudolf Kaaks
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

View more
  7 in total

Review 1.  Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Rosaria Vincenza Giglio; Marcello Ciaccio; Manfredi Rizzo
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 6.208

Review 2.  The Insulin-like Growth Factor System and Colorectal Cancer.

Authors:  Nikola Gligorijević; Zorana Dobrijević; Miloš Šunderić; Dragana Robajac; Danilo Četić; Ana Penezić; Goran Miljuš; Olgica Nedić
Journal:  Life (Basel)       Date:  2022-08-20

3.  A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.

Authors:  Javier Robles; Laura Pintado-Berninches; Issam Boukich; Beatriz Escudero; Vivian de Los Rios; Rubén A Bartolomé; Marta Jaén; Ángela Martín-Regalado; María Jesús Fernandez-Aceñero; Juan Ignacio Imbaud; José Ignacio Casal
Journal:  J Pathol Clin Res       Date:  2022-09-22

4.  Destruxin B Suppresses Drug-Resistant Colon Tumorigenesis and Stemness Is Associated with the Upregulation of miR-214 and Downregulation of mTOR/β-Catenin Pathway.

Authors:  Szu-Yuan Wu; Yan-Jiun Huang; Yew-Min Tzeng; Chi-Ying F Huang; Michael Hsiao; Alexander T H Wu; Tse-Hung Huang
Journal:  Cancers (Basel)       Date:  2018-09-25       Impact factor: 6.639

Review 5.  Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications.

Authors:  Aldona Kasprzak; Agnieszka Adamek
Journal:  Int J Mol Sci       Date:  2019-10-03       Impact factor: 5.923

Review 6.  Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors.

Authors:  Aldona Kasprzak; Witold Szaflarski
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

7.  TGF-β-induced IGFBP-3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion.

Authors:  Rocío Navarro; Antonio Tapia-Galisteo; Laura Martín-García; Carlos Tarín; Cesáreo Corbacho; Gonzalo Gómez-López; Esther Sánchez-Tirado; Susana Campuzano; Araceli González-Cortés; Paloma Yáñez-Sedeño; Marta Compte; Luis Álvarez-Vallina; Laura Sanz
Journal:  Mol Oncol       Date:  2020-09-01       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.